|
1
|
Siegel RL, Miller K and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2018. View Article : Google Scholar
|
|
2
|
2016 Taiwan Cancer Registry. simplehttps://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227April
4–2020
|
|
3
|
Shuch B, Amin A, Armstrong AJ, Eble JN,
Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI and Kutikov A:
Understanding pathologic variants of renal cell carcinoma:
Distilling therapeutic opportunities from biologic complexity. Eur
Urol. 67:85–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
COSMIC Cancer Browser. simplehttps://cancer.sanger.ac.uk/cosmic/browse/tissue?wgs=off&sn=kidney&ss=NS&hn=carcinoma&sh=clear_cell_renal_cell_carcinoma&in=t&src=tissue&all_data=nFebruary
15–2020
|
|
5
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim WY and Kaelin WG: Role of VHL gene
mutation in human cancer. J Clin Oncol. 15:4991–5004. 2004.
View Article : Google Scholar
|
|
7
|
Xing T and He H: Epigenomics of clear cell
renal cell carcinoma: Mechanisms and potential use in molecular
pathology. Chin J Cancer Res. 28:80–91. 2016.PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu C, Ranjbar MR, Wu Z, DiCarlo J and Wang
Y: Detecting very low allele fraction variants using targeted DNA
sequencing and a novel molecular barcode-aware variant caller. BMC
Genomics. 18:52017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H and Durbin R: Fast and accurate short
read alignment with burrows-wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A mapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cibulskis K, Lawrence MS, Carter SL,
Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES
and Getz G: Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
31:213–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McLaren W, Pritchard B, Rios D, Chen Y,
Flicek P and Cunningham F: Deriving the consequences of genomic
variants with the ensembl API and SNP effect predictor.
Bioinformatics. 26:2069–2070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brugarolas J: Molecular genetics of
clear-cell renal cell carcinoma. J Clin Oncol. 32:1968–1976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaelin WG Jr: The von hippel-lindau tumor
suppressor protein and clear cell renal carcinoma. Clin Cancer Res.
13:680s–684s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Posadas EM, Limvorasak S and Figlin RA:
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol.
13:496–511. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kondo K, Yao M, Yoshida M, Kishida T,
Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, et
al: Comprehensive mutational analysis of the VHL gene in sporadic
renal cell carcinoma: Relationship to clinicopathological
parameters. Genes Chromosomes Cancer. 34:58–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hodges C, Kirkland JG and Crabtree GR: The
many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold
Spring Harb Perspect Med. 6(pii): a0269302016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Varela I, Tarpey P, Raine K, Huang D, Ong
CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al: Exome
sequencing identifies frequent mutation of the SWI/SNF complex gene
PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nargund AM, Pham CG, Dong Y, Wang PI,
Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, et al:
The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear cell
renal cell carcinoma. Cell Rep. 18:2893–2906. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pfister SX, Ahrabi S, Zalmas LP, Sarkar S,
Aymard F, Bachrati CZ, Helleday T, Legube G, La Thangue NB, Porter
AC and Humphrey TC: SETD2-Dependent histone H3K36 trimethylation is
required for homologous recombination repair and genome stability.
Cell Rep. 7:2006–2018. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiang YC, Park IY, Terzo EA, Tripathi DN,
Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, et
al: SETD2 haploinsufficiency for microtubule methylation is an
early driver of genomic instability in renal cell carcinoma. Cancer
Res. 78:3135–3146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanu N, Gronroos E, Martinez P, Burrell
RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M, Rowan AJ,
Patel H, et al: SETD2 loss-of-function promotes renal cancer
branched evolution through replication stress and impaired DNA
repair. Oncogene. 34:5699–5708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carbone M, Yang H, Pass HI, Krausz T,
Testa JR and Gaudino G: BAP1 and cancer. Nat Rev Cancer.
13:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao
A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L,
Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang A, Garraway LA, Ashworth A and Weber
B: Synthetic lethality as an engine for cancer drug target
discovery. Nat Rev Drug Discov. 19:23–38. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim HS, Kim JH, Jang HJ, Han B and Zang
DY: Clinicopathologic significance of VHL gene alteration in
clear-cell renal cell carcinoma: An updated meta-analysis and
review. Int J Mol Sci. 19:E25292018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salinas-Sanchez AS, Serrano-Oviedo L,
Nam-Cha SY, Roche-Losada O, Sánchez-Prieto R and Giménez-Bachs JM:
Prognostic value of the VHL, HIF-1α, and VEGF signaling pathway and
associated MAPK (ERK1/2 and ERK5) pathways in clear-cell renal cell
carcinoma. A long-term study. Clin Genitourin Cancer. 15:e923–e33.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
da Costa WH, Rezende M, Carneiro FC, Rocha
RM, da Cunha IW, Carraro DM, Guimaraes GC and de Cassio Zequi S:
Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic
marker in clear cell renal cell carcinoma. BJU Int. 113:E157–E163.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pawlowski R, Muhl SM, Sulser T, Krek W,
Moch H and Schraml P: Loss of PBRM1 expression is associated with
renal cell carcinoma progression. Int J Cancer. 132:E11–E117. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kapur P, Christie A, Raman JD, Then MT,
Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, et
al: BAP1 immunohistochemistry predicts outcomes in a
multi-institutional cohort with clear cell renal cell carcinoma. J
Urol. 191:603–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hakimi AA, Ostrovnaya I, Reva B, Schultz
N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, et al:
Adverse outcomes in clear cell renal cell carcinoma with mutations
of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and
the KIRC TCGA research network. Clin Cancer Res. 19:3259–3267.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SH, Park WS, Park EY, Park B, Joo J,
Joung JY, Seo HK, Lee KH and Chung J: The prognostic value of BAP1,
PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue
markers in localized renal cell carcinoma: A retrospective study of
tissue microarrays using immunohistochemistry. PLoS One.
12:e01796102017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Manley BJ, Zabor EC, Casuscelli J,
Tennenbaum DM, Redzematovic A, Becerra MF, Benfante N, Sato Y,
Morikawa T, Kume H, et al: Integration of recurrent somatic
mutations with clinical outcomes: A pooled analysis of 1049
patients with clear cell renal cell carcinoma. Eur Urol Focus.
3:421–427. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ricketts CJ, De Cubas AA, Fan H, Smith CC,
Lang M, Reznik ED, Bowlby R, Gibb EA, Akbani R, Beroukhim R, et al:
The cancer genome atlas comprehensive molecular characterization of
renal cell carcinoma. Cell Rep. 23:313–326. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corces MR, Granja JM, Shams S, Louie BH,
Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW, et al:
The chromatin accessibility landscape of primary human cancers.
Science. 362:eaav18982018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Data published by the Taiwanese National
Health Insurance Administration. simplehttps://www.nhi.gov.tw/Content_List.aspx?n=7157A9A3E2A3B110&topn=3FC7D09599D25979April
4–2020
|
